SynthesisPloS one2017
Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: An updated systematic review and meta-analysis with trial sequential analysis.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- 5-HTInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Pooled it
- Efficacy and safety of ondansetron for morning sickness in pregnancy: a systematic review of clinical trials.Frontiers in pharmacology · 2023Pooled it
- Comparison of ondansetron and tropisetron in preventing postoperative nausea and vomiting: A meta-analysis of randomized controlled trials.Saudi medical journal · 2021Pooled it
- Pooled it
- Comparison of ramosetron and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a meta-analysis of randomized controlled trials.The Journal of international medical research · 2019Pooled it
- Fosaprepitant versus Ondansetron for Preventing Postoperative Nausea and Vomiting After Video-Assisted Thoracoscopic Lung Resection: A Randomized Controlled Clinical Trial.Drug design, development and therapy · 2026Trial
- Penehyclidine mitigates postoperative nausea and vomiting and intraoperative oculocardiac reflex in patients undergoing strabismus surgery: a prospective, randomized, double-blind comparison.BMC anesthesiology · 2021Trial
- The effectiveness of ramosetron and ondansetron for preventing postoperative nausea and vomiting after arthroscopic rotator cuff repair: a randomized controlled trial.Journal of orthopaedic surgery and research · 2020Trial
- Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting.BMC cancer · 2025Article
- Optimal dosing regimen of ondansetron oral soluble pellicles for preventing postoperative nausea and vomiting after primary total joint arthroplasty: a randomized controlled clinical trial.Frontiers in medicine · 2025Article
- Cost-effectiveness of prophylactic ramosetron in the prevention of postoperative nausea and vomiting.PloS one · 2024Article
- Comparison of the Effectiveness of Palonosetron and Ramosetron in Preventing Postoperative Nausea and Vomiting: Updated Systematic Review and Meta-Analysis with Trial Sequential Analysis.Journal of personalized medicine · 2022Review
- Effects of Ramosetron on Nausea and Vomiting Following Spinal Surgery: A Meta-Analysis.Current therapeutic research, clinical and experimental · 2022Review
- Effect of ondansetron for preventing postoperative nausea and vomiting after breast cancer surgery.American journal of translational research · 2022Article
- In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs.International journal of molecular sciences · 2021Article
- A history of severe nausea and vomiting during pregnancy predicts a higher incidence of postoperative nausea and vomiting after breast cancer surgery without breast reconstruction.Breast cancer (Tokyo, Japan) · 2021Article
- A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HTInternational journal of analytical chemistry · 2021Article
- Postoperative Nausea and Vomiting in Pediatric Patients.Paediatric drugs · 2021Review
- Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review.F1000Research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative nausea and vomiting is a distressing complication of surgery, and 5-HT3 receptor antagonists are often prescribed to prevent it. Ondansetron is the agent typically administered to prevent postoperative nausea and vomiting. Although ramosetron has a longer duration of action than ondansetron, it remains unclear whether ramosetron is the more effective medication. We performed an updated meta-analysis on the comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting.
methodsWe searched six databases for all trials that randomly assigned patients to ramosetron or ondansetron groups. The primary outcome was postoperative nausea or vomiting in the early, late, and next-day periods. The secondary outcomes were side effects of the medications. We used the random-effects model to combine the results. Trial sequential analyses were performed to correct for repetitive testing in the updated meta-analysis.
resultsTwenty-seven randomized controlled trials with 3,811 patients were included in the meta-analysis. The combined results of ramosetron vs. ondansetron efficacy in preventing postoperative nausea and vomiting were as follows: Risk ratio [95% confidence interval] = 0.82 [0.69-0.98] for early postoperative nausea, 0.76 [0.65-0.89] for late postoperative nausea, 0.69 [0.57-0.84] for next-day postoperative nausea, 0.78 [0.63-0.98] for early postoperative vomiting, 0.57 [0.45-0.72] for late postoperative vomiting, and 0.61 [0.43-0.86] for next-day postoperative vomiting. Dizziness was significantly lower in ramosetron groups than in ondansetron groups (risk ratio [95% confidence interval] = 0.81 [0.66-0.98]). Trial sequential analysis revealed that the results for late postoperative nausea, late postoperative vomiting, and next-day postoperative nausea were conclusive.
conclusionsRamosetron is more effective in preventing late postoperative nausea, late postoperative vomiting, and next-day postoperative nausea than ondansetron. The incidence of dizziness may be lower in patients receiving ramosetron than in patients receiving ondansetron.
trial registrationUniversity hospital Medical Information Network Clinical Trials Registry: UMIN000022980.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.